Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Surgical Oncology Clinics of North America, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of surgical oncology and surgery, captivating readers since its inception in 1995. With ISSN 1055-3207 and E-ISSN 1558-5042, this esteemed journal offers a comprehensive platform for the dissemination of cutting-edge research, clinical studies, and expert reviews pertaining to surgical techniques and oncological advancements. The journal currently holds a commendable Q3 ranking in Oncology and a Q2 ranking in Surgery, underpinned by its impressive Scopus rankings that place it in the top 25% of its category in Medicine, particularly in the surgical domain (Rank #137/551). Although it does not operate under an open-access model, the insights shared within its pages are invaluable for researchers, healthcare professionals, and students dedicated to enhancing patient outcomes in surgical oncology. With a commitment to advancing medical knowledge, Surgical Oncology Clinics of North America remains a crucial resource for those pursuing excellence in surgical practices and oncology treatment methodologies.

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

Case Reports in Oncology is a peer-reviewed journal published by KARGER, dedicated to the dissemination of high-quality case studies and clinical reports in the field of oncology. Since its transition to Open Access in 2008, this Swiss-based journal has aimed to broaden the accessibility of key findings to a global audience of researchers, healthcare professionals, and students. The journal is positioned in the Q3 quartile for oncology, indicating its valuable contribution to the field, while also holding a Scopus rank of 294 out of 404 in Medicine, with a percentile of 27%. However, its open access model ensures that even those outside of traditional academic institutions can engage with critical advancements and novel insights from the oncology community. With a publication span extending from 2010 to 2024, Case Reports in Oncology serves as a crucial platform for sharing unique clinical experiences and innovative treatment strategies, ultimately enriching the practice and study of oncology.

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

Oncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

Rare Tumors, published by SAGE Publications Ltd, is a premier open-access journal dedicated to advancing the understanding and research of rare neoplasms. With the ISSN 2036-3605 and E-ISSN 2036-3613, this journal provides a vital platform for sharing innovative research findings and clinical insights since its inception in 2009. Situated in Italy, Rare Tumors has a converged publication timeline from 2010 to 2024 and aims to foster a supportive community for researchers and professionals in the oncology and histology fields. It has achieved a notable Q3 ranking in Oncology and Q4 in Histology as of 2023, reflecting its crucial role in bridging the knowledge gap in these specialized areas. Despite its relatively humble Scopus ranks, the journal's open-access model ensures that vital information reaches a broad audience, including those in academia, clinical practice, and beyond. It aspires to not only document rare tumor cases but also stimulate dialogue on their diagnosis, treatment, and management strategies, making it an indispensable resource for anyone dedicated to tackling the challenges posed by rare tumors.